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Background. Children aﬀected by neurodevelopmental disability could experience early pubertal changes at least 20 times more
than the general population. Limited data about central precocious puberty (CPP) among children aﬀected by cerebral palsy
(CP) are available. Methods. This is a longitudinal, observational, retrospective, case-control study involving 22 children
aﬀected by CPP and CP (group A), 22 paired with CP but without CPP (group B), and 22 children with CPP without CP.
Auxological, biochemical, and instrumental data were collected at diagnosis of CPP and at 2 follow-up visits. Results. No
diﬀerences were detected between groups A (at baseline) and B. At diagnosis of CPP, height SDS adjusted for target height
(H-TH SDS) was signiﬁcantly reduced in A than in C (−0.63 ± 1.94 versus 1.56 ± 1.38), while basal LH and oestradiol levels
were signiﬁcantly elevated in A than in C. During follow-up, despite an eﬀective treatment, growth impairment deteriorated
in A than in C (Δ H-SDS from diagnosis of CPP to last follow-up: −0.49 ± 0.91 versus 0.21 ± 0.33, p = 0 023). Conclusions.
Diagnosis of CPP could be partially mislead in CP due to growth failure that got worse during follow-up despite therapy. CPP
in CP seems to progress rapidly along time supporting the hypothesis of a more intense activation of hypothalamic-pituitary-
gonadal-axis in these patients.
1. Introduction
Many insults to central nervous system can cause central
precocious puberty (CPP), including traumatic brain injury,
birth asphyxia, congenital malformation, infections, and
several tumours. Moreover, CPP has been also described
in a long list of genetic disorders including neuroﬁbroma-
tosis, fragile X syndrome, and tuberous sclerosis. An old-
fashioned study published in 1999 reviewed records of
15719 patients with neurodevelopmental disabilities to
detect diagnostic data for premature sexual development:
CPP was identiﬁed in 32 children, with the earliest
changes seen in one girl at 1 year and 7 months of age
with a primary diagnosis of cerebral palsy (CP) [1]. These
ﬁrst data documented that children with a neurodevelop-
mental disability are 20 times more at risk of premature
pubertal changes when compared to general population.
CP, also called nonprogressive childhood encephalopathy,
is a common and lifelong condition caused by a brain lesion
occurred during structural and functional maturation of the
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brain in the pre-, peri-, or postnatal period. Despite the
high rate of cumulative incidence of CP (estimated 2–2.7
cases for every 1000 live births) [2], the number of studies
analysing CPP in CP is limited [3, 4]. In 2002, a survey
performed over 207 CP children aged from 3 to 18 years
with moderate to severe motor impairment documented
that sexual maturation diﬀers in CP from the general popula-
tion: white girls with CP initiated pubic hair development
earlier than the general population, but the age in the onset
of breast development was similar and the estimated median
age of menarche was even later (about 1.3 years) than for the
general population. The same trend was described for white
CP boys [4]. Nevertheless, even that survey, still considered
the more recent paper published on this topic, did not
mention CPP.
The objectives of this study include the detection of
speciﬁc features of CPP in patients with CP to establish the
need of a proper diagnostic and therapeutic approach and
to analyse the aetiological complexity of their association.
2. Patients and Methods
This is a descriptive, longitudinal, observational, retrospec-
tive, case-control study.
The study population was enrolled among children
followed up at the paediatric endocrine and neurologic
outpatient clinics at three Italian academic centres (Modena,
Messina, and Perugia) between January 2001 and December
2014. The sample comprised children with CP and CPP
(group A), children with CP without CPP (group B) matched
for gender and age with participants of group A, and children
with CPP without CP (group C).
None of the children included in this study presented a
history of concomitant genetic, metabolic, neurodegenerative
disease. Cases of peripheral precocious puberty were ruled
out. The mobility and motor impairment of CP patients
was classiﬁed as levels III, IV, and V according to the Gross
Motor Function Classiﬁcation System (GMFCS) [5].
Anamnestic data comprised gestational and birth infor-
mation, including birth anthropometric data, comorbidities,
and concomitant therapies, especially the use of antiepileptic
drugs (AED).
Recorded anthropometric measurements for all partici-
pants included length (L) (groups A and B) or standing
height (H) (group C), body weight, body mass index (BMI),
growth velocity (GV), and the Tanner stage of sexual
maturation [6]. In every centre, length/height was measured
to the nearest 0.1 cm with a horizontal level- or wall-
mounted stadiometer (Harpenden; Crymych, UK); body
weight was measured to the nearest 0.1 kg; and BMI was
obtained from the weight in kg/length or height in meters
squared and expressed as standard deviation score (SDS)
with respect to chronological age. Height SDS and BMI
SDS were calculated for each value using age- and sex-
speciﬁc World Health Organization (WHO) growth chart
2007 [7]. Parental height was also collected, when available,
to estimate target height (TH), calculated according to the
following formulas in cm: [(mother’s height + 13) + father’s
height]/2 in males and [(mother’s height− 13) + father’s
height]/2 in females [8]. Each value of height SDS was also
adjusted for TH.
Plasma basal levels of follicle stimulating hormone
(FSH), luteinizing hormone (LH) expressed in mUI/ml,
oestradiol (pg/ml), or testosterone (ng/dl) were detected
through chemiluminescent immunometric assay (Bayer,
Germany) at baseline and at each follow-up examination.
In all patients with signs of early pubertal development
(groups A and C), GnRH test (LHRH, Ferring, Kiel,
Germany; i.v. bolus injection of 100 mcg/m2) was performed.
An indwelling venous catheter was inserted into an antecubi-
tal vein and kept patent by a slow saline infusion. Tests on
blood samples were performed before and at 0, 15, 30, 45,
60, and 90min after LHRH injection to measure LH, FSH,
and oestradiol concentrations.
X-ray of the left (or nondominant) wrist and hand was
taken for bone age (BA) assessment according to the
Greulich & Pyle method at baseline and annually during
follow-up in groups A and C. All patients underwent
brain MRI.
Data about the therapeutic approach to CPP (Triptore-
lin) including time interval (28 or 21 days) and the dose of
subcutaneous injection (1.875 or 3.75mg) were gathered
from folders of all patients of groups A and C.
The study was approved by the Ethics Committee of the
University of Modena and Reggio Emilia (Practice 255/13).
The results were expressed as mean and SDS for
quantitative variables or as percentages for qualitative
variables. Comparison among groups was performed using
the Mann–Whitney nonparametric test (STATISTICA TM
software, StatSoft Inc., Tulsa, OK, USA), and comparison
among variables of the same group over time was analysed
through the Wilcoxon test. The level of signiﬁcance was set
at p < 0 05.
3. Results
We enrolled 44 Caucasian children with CP: 22 presenting
CPP (group A) and 22 without CPP (group B). Group C
was composed of 22 Caucasian CPP children without CP.
Table 1 lists baseline features of groups. The majority
of CP patients were on AED: 41% and 54% were on leve-
tiracetam, 36% and 54% on valproic acid, 23% and 18%
on etosuccimide, 18% and 9% on phenobarbital, 9% and
14% on topiramate, and 4.5% and 14% on gabapentin,
respectively, in groups A and B. Most of these patients
were on multidrug regimen.
One patient in group A and another one in group B were
also on levothyroxine because of hypothyroidism. No other
endocrine disease, apart from CPP, was identiﬁed in the
study population.
No diﬀerences in anthropometric parameters were
detected among CP patients at the time of diagnosis of CPP
(A versus B: length SDS −0.72±1.86 versus −0.53±1.88,
p = 0 56; BMI SDS 0.67±1.31 versus 0.18± 1.58, p = 0 35).
Performing the analysis according to gender, both females
and males with CP and presenting CPP have an increased
BMI SDS in comparison to group B; nevertheless, the
diﬀerence was not statistically signiﬁcant (A versus B:
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females 0.58 ±1.24 versus 0.04±1.71, p = 0 40; males 1.11±
1.72 versus 0.52±1.33, p = 0 71).
Comparing CPP groups (A versus C), the age of diag-
nosis of CPP did not diﬀer signiﬁcantly, even if CP children
tended to present CPP earlier (Table 2), and the younger
patient with a diagnosis of CPP was a boy with CP aged
2 years and 9 months. At the diagnosis of CPP, CP children
were shorter than those in group C, even if length SDS was
adjusted for TH (Table 2). Development of sexual matura-
tion was distributed diﬀerently in 2 groups according to the
Tanner stage (Figure 1). Similarly, basal LH and oestradiol
levels were higher in group A than in C, whereas basal FSH
and gonadotrophin values after stimulation test did not
diﬀer (Table 3).
In group A, two families refused therapy with
gonadotrophin-releasing hormone agonist (GnRHa) after
the diagnosis of CPP: features of these 2 patients were
collected at baseline, but not later. Follow-up lasted 24.80±
15.18 (range 7–72) months. At the second follow-up visit,
all patients were still on GnRHa. Over time, GnRHa therapy
aﬀected diﬀerently the growth in the 2 groups: length/height
SDS and height SDS adjusted for TH continued to get worse
in group A than in group C (Table 2) and at the end of
follow-up, the discrepancy among recorded values of height
SDS adjusted for TH deteriorated in group A but not in
group C (−0.49± 0.91 versus 0.21± 0.33, p = 0 023, resp.)
and GV signiﬁcantly reduced only in group A, even in
comparison with group C.
Despite diﬀerent growth patterns, GnRHa therapy was
eﬀective in both groups decreasing basal gonadotropin and
oestradiol/testosterone levels (Table 3) and reducing the
signs of pubertal progression (Figure 1).
The advancement of bone age in comparison with chro-
nological age was stable over time in group C, while was
progressively reduced in group A. In all the study groups,
brain MRI did not identify anomalies in hypothalamic-
pituitary region.
The dose of GnRHa started at 1.875mg only in 2 patients
belonging to group A according to their age and/or weight.
The remaining patients in group A and all patients of group
C were on Triptorelin at the dose of 3.75mg. The time
interval between injections corresponded to 21 days for
32% of group A patients, but for none of group C (on regular
monthly injection).
4. Discussion
CP is a complex condition that aﬀects individuals diﬀerently.
Its treatment and management are challenging because
families, caregivers, and clinicians have to face, besides
motor, cognitive, and neurologic disorders, also nutritional
and respiratory concerns, infections, osteoporosis, and more
rare endocrine problems [9]. Data from Worley et al.
described the physiological pattern of pubertal development
observed in 207 CP children with moderate to severe motor
impairment: girls seemed to enter puberty earlier but tended
Table 1: Baseline features of groups A, B, and C.
Group A Group B Group C
Num. (F/M) 22 (18/4) 22 (17/5) 22 (22/0)
Baseline age (years) (mean± SDS; range) 6.42± 1.74 (2.74–8.90) 6.63± 1.85 (2.10–9.70) 7.02± 0.79 (5.20–7.96)
Gestational age (weeks) (mean± SDS) 36.93± 4.61 37.94± 4.11 39.33± 0.70
Apgar 1min (mean± SDS)° 4.58± 3.02 3.23± 2.24 9.01± 0.54
Apgar 5min (mean± SDS)° 6.25± 2.56 5.00± 1.80 9.50± 0.22
Birth weight (kg) (mean± SDS) 2.65± 0.85 3.04± 0.84 3.33± 0.35°
GMFCS (III, IV, V) (%) 68, 27, 5 73, 18, 9 NA
Use of antiepileptic medication (%) 77% 100% 0%
°Signiﬁcant diﬀerence between groups A and C.
Table 2: Longitudinal evaluation of anthropometric features of patients with CPP at baseline (diagnosis of CPP) and during GnRHa
treatment. H-TH SDS: height SDS adjusted for target height (TH).
Baseline 1st follow-up visit° 2nd follow-up visit°
Group A Group C Group A Group C Group A Group C
Chronological age (CA) 6.42± 1.74 7.02± 0.79 7.50± 1.75° 8.02± 0.90° 8.59± 2.15° 8.69± 0.55°
Height SDS −0.72± 1.86 0.75± 1.46^ −0.96± 1.86 0.87± 1.38^ −1.32± 1.63 0.76± 1.70^
H-TH SDS −0.63± 1.94 1.56± 1.38^ −0.72± 1.90 1.68± 1.26^ −1.07± 1.83 1.48± 1.42^
Discrepancy between bone age (BA) and CA 1.74± 1.18 1.74± 1.57 1.07± 1.01° 1.65± 0.98 0.72± 0.65° 0.89± 0.43
Growth velocity (cm/years) 6.67± 1.22 9.1± 0.99 5.61± 1.99 6.70± 1.34 4.51± 3.04° 6.60± 1.30^
BMI SDS 0.67± 1.31 0.45± 0.82 0.15± 1.54° 0.57± 1.02 0.52± 1.21 0.24± 0.98
°Signiﬁcant diﬀerence in the same group from baseline. ^Signiﬁcant diﬀerence between the groups at the speciﬁc time point.
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to mature over a longer period of time, menstruating later;
boys followed more regular patterns but tended to start
earlier [4]. The evaluation of CPP in CP and its prevalence
lay outside the scope of the mentioned study. A higher
prevalence of variable degrees of early sexual maturation
was described among 161 girls with neonatal encephalopathy
in comparison to general population (4.3% versus 0.6%) [3].
However, limited data have been published on this topic [1]
and most of the already published papers evaluated wide
populations of children with variable degree of neurodeve-
lopmental disabilities, and not exclusively CP [1, 3]. Our
study focused on the association between CP and CPP, even
if, because of its design, no data about the prevalence of their
association could be deduced.
Precocious puberty is reported 8 times more frequently in
girls than in boys, and underlying organic disorders are more
commonly discovered in males [10]. Strikingly, in our study,
4 of 22 children with CP and CPP were male, whereas only
females composed group C.
Even if ages at baseline did not diﬀer between groups A
and C (Table 2), our results evoke a precocity of the age in
the onset of CPP in CP than in the general population.
Moreover, CPP seems to progress rapidly in CP: at the
diagnosis of CPP, a great percentage of CP patients presented
a more advanced pubertal stage (Figure 1) and higher levels
of basal LH and oestradiol were documented in group A than
in group C (Table 3). These data let us suppose a more
intense activation of the hypothalamic-pituitary-gonadal axis
in CP that might be due to a loss of normal childhood
hypothalamic inhibition of pituitary gonadotropins. Severe
brain damage and AED may aﬀect a number of neurotrans-
mitter pathways involved in gonadotropin control [11]. In
our study, brain neuroimaging was performed in all CP
patients, without ﬁnding abnormalities in hypothalamic-
pituitary region. Moreover, the majority of CP patients were
on AED treatment independently from CPP.
In our cohort of patients, the lack of statistical diﬀerence
between the age of diagnosis of CPP in group A and in C
could be explained by the hypothesis that in CP, even in
the presence of signs of pubertal developmental, the diagno-
sis of CPP could be delayed: ﬁrst of all, parents or caregivers
could underestimate the problem due to the complexity and
severity of the general physical condition of the patient and,
additionally, a growth failure could partially mislead the
initial picture. In fact, as already reported in literature,
children with CP are usually aﬀected by growth impairment
[12, 13]. In CP, growth retardation might have a multifacto-
rial aetiology, and it could be associated with nonnutritional
Table 3: Longitudinal evaluation of biochemical data of patients with CPP at baseline (diagnosis of CPP) and during GnRHa treatment.
Baseline 1st follow-up visit 2nd follow-up visit
Group A Group C Group A Group C Group A Group C
LH (mUI/ml) 2.54± 2.23 0.49± 0.50^ 0.58± 0.56 0.28± 0.17 0.48± 0.55 0.28± 0.15
FSH (mUI/ml) 5.34± 5.96 3.44± 1.41 1.86± 1.78 0.78± 0.57 2.65± 2.18 0.47± 0.25
Oestradiol (pg/ml) 27.13± 16.92 12.65± 6.94^ 12.36± 6.72 11.93± 2.94 11.13± 3.02 11.28± 2.21
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(%
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Figure 1: Pubertal stages according to Tanner and Whitehouse [6] in patients with CPP at baseline (diagnosis of CPP) and during GnRHa
treatment. Fu: follow-up.
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factors: the type of movement disorder, the severity of CP,
mainly regarding self-feeding and walking capacity, the level
of physical activity limitation, and endocrine disorders seem
to act synergistically. Typical pubertal growth spurt appears
to be signiﬁcantly diminished in CP children [14]. Other
descriptive data conﬁrm a steady height velocity before and
during puberty in CP [15]. Lower concentrations of insulin-
like growth factor 1 (IGF-1) and of growth hormone (GH)
were described in girls with CP, with a similar trend for
boys, supporting the hypothesis of a dysfunction of the
hypothalamic-pituitary axis [16]. In our study, the obser-
vation of a signiﬁcant reduction of growth velocity over
follow-up and of a progressive increase of discrepancy
between patient’s height SDS and familiar target height
over time (Table 2) supports the hypothesis of a complex
growth disorder in CP.
The relationship between sexual maturation and nutri-
tional status has to be considered in CP. More advanced
sexual maturation was associated with more body fat in girls,
but with less body fat in boys [4]. Our data did not support
the aetiological role of BMI in developing CPP in CP: no
changes in BMI SDS were documented between groups A
and C over follow-up and, more interestingly, between
groups A and B at the time of diagnosis of CPP. Nevertheless,
we cannot consider BMI as a reliable indicator of nutritional
status. The use of BMI in a traditional manner in children
with reduced muscle mass, as happened in CP, could inad-
vertently result in an overestimation of their nutritional
status [17]. Other tools such as waist and hip circumferences,
skin-fold thickness together with serum leptin levels should
be measured in CP children in future studies [18].
Patients with CP and only minimal motor dysfunction
can be expected to achieve weights and heights close to
those of sex- and age-matched general population, while
the discrepancy increases in patients with signiﬁcant motor
dysfunction. Therefore, the use speciﬁc growth charts are
encouraged [15, 19]. In our study, we decide to collect CP
statural data instead of segmental measurements and to
compare them to standard chart in order to better underline
diﬀerences among groups. Moreover, we agree with the
US Centre for Disease Control and Prevention: these
population-speciﬁc growth charts describe “how CP patients
grow” rather than “how they should grow” and, therefore,
could minimize their growth disturbance [20]. CP is diﬀerent
from some genetic conditions that are known to alter
growth. CP is a condition that only has “the potential to
alter growth” [14].
For families (taking care of children who present severe
motor impairment), the reduction in ﬁnal growth, occurring
usually in CPP when untreated, could appear even conve-
nient: lifting, transferring, and transporting child may be
easier at a smaller size. Considering the international debate
about the theme of attenuating growth in children with
serious disabilities [21–23], we intentionally avoid dealing
with any ethical issues in this paper: any therapeutic decision
should consider the peculiarity of each case and could be
diﬀerent for every family. Generally, in childhood, the major
goals in the medical management of CPP include halting
the advancement of bone age, arresting secondary sexual
development, and optimizing adult height. Other treatment
issues could include the child’s emotional changes to CPP
and the family’s worries [24]. In our study, we document that
during follow-up, despite GnRHa therapy, growth failure in
CP seemed to worsen. This ﬁnding imposes clinicians to
redeﬁne the realistic objectives of GnRHa when treating CP
patients and/or to identify other therapeutic options to
optimize results. In this prospective, other eﬀorts should be
done to understand the aetiology of CPP in CP. In fact,
considering the multiple neurotrophic eﬀects of GH-IGF-1
axis in both central and peripheral nervous system, some
cognitive disorders characterizing CP have been documented
to reverse by GH replacement [25]. Similarly, other hor-
mones, especially reproductive steroids and oestradiol, have
some neuroactive properties and, at the same time, epileptic
substrate seems to be susceptible to neuroactive sexual
steroid eﬀects [26]. As happened for hypothalamic gelastic
seizure [27] and for catamenial epilepsy [28], we can now
only speculate that GnRHa could not only inﬂuence the
development of pubertal progression but also help in control-
ling the potential concomitant deterioration of neurologic
symptoms as seizures in CP. Because our study did not
include data on these neurological aspects (e.g., frequency
and type of seizure, plasmatic levels of AEDs), further speciﬁc
studies are needed.
5. Conclusion
Our data clearly demonstrated the challenge of the diagnosis
and the speciﬁc peculiarities of CPP in CP. Firstly, health-
care providers have to be vigilant in screening for early
pubertal changes in children with CP despite the presence
of growth failure; then, they have to critically select the
correct tools to detect anthropometric and nutritional status
and, ﬁnally, they have to understand and redeﬁne the
purposes of the management of CPP in CP to better support
parents in order to ensure the best therapeutic choice for
each patient.
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